Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Jürgen K. Rockstroh"'
Autor:
J Emmelkamp, Jürgen K. Rockstroh
Publikováno v:
Expert Opinion on Drug Safety. 7:559-569
Maraviroc represents the first licensed CCR5 co-receptor antagonist from the new antiretroviral (ARV) drug-class of entry inhibitors.Results of Phase III clinical trials in three-drug-class experienced patients have presented maraviroc as a promising
Autor:
Martin Vogel, Jürgen K. Rockstroh
Publikováno v:
Expert Opinion on Drug Safety. 4:403-420
Kaletra, a fixed-dose co-formulation of lopinavir/ritonavir, was the first boosted protease inhibitor developed for the treatment of HIV-infection. In September 2000, the US FDA granted Kaletra fast-track approval as data showed a higher efficacy in